Lipotoxicity-causing fatty acid overexposure and accretion in lean tissues leads to insulin resistance and impaired pancreatic β-cell function - the hallmarks of T2D - contributing to associated complications such as heart failure, kidney failure and microvascular diseases. Proper dietary fatty acid (DFA) storage in white adipose tissue (WAT) is now thought to prevent lean-tissue lipotoxicity. Using novel Positron-Emission Tomography (PET) and stable isotopic tracer methods which were developed in Sherbrooke, the investigator showed that WAT storage of DFA is impaired in people with pre-diabetes or T2D. The investigator also showed that this impairment is associated with greater cardiac DFA uptake, as well as subclinical left-ventricular systolic and diastolic dysfunction. Then, It has been found that modest weight loss in pre-diabetics, after a one-year lifestyle intervention, improved WAT DFA storage, curbed cardiac DFA uptake, and restored associated left-ventricular dysfunction. It has been also found that a 7-day low-saturated fat, low-calorie diet raised insulin sensitivity but did not restore WAT or cardiac DFA metabolism. Whether WAT DFA storage directly impacts cardiac DFA uptake is not known. Importantly, the investigator recently uncovered marked sex-specific differences in WAT DFA metabolism. These may explain, at least in part, sex-related differences in the cardiac DFA uptake, which occurs in pre-diabetes. Higher spillover of WAT DFA into circulating Non-Esterified Fatty Acid (NEFA) appears to be linked in women to greater cardiac DFA uptake, as opposed to direct cardiac chylomicron triglycerides (TG) uptake in men. Here, the investigator will isolate and compare organ-specific fatty acid uptake occurring postprandially from chylomicron-TG vs. NEFA pools, as well as the oxidative vs. non-oxidative intracellular metabolic pathways associated with increased cardiac DFA uptake in pre-diabetic men and women.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
50
oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
centre de recherche du CHUS
Sherbrooke, Quebec, Canada
Plasma NEFA appearance rate
NEFA appearance will be measured using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min, as slightly modified from previous descriptions, using Steele's non steady-state equations. Blood samples to measure plasma palmitate, oleate, linoleate, and total NEFA levels, \[7,7,8,8-2H\]-palmitate enrichments by GC/MS-MS.
Time frame: 2 years
Cardiac and hepatic uptake
will be determined using 11C-palmitate PET/CT. 180 MBq will be administered by bolus injection at postprandial time 90min. After a transmission scan and regional CT (40mA), a 30-min dynamic list-mode PET acquisition will be performed starting at time 90 min on a 18 cm-high thoraco-abdominal segment to include the left cardiac ventricle and most of the liver on a Philips Gemini TOF PET/CT
Time frame: 2 years
WAT spillover NEFA appearance rates
WAT spillover NEFA will be determined from oral administration of \[U-13C\]-palmitate. Blood samples to measure plasma \[U-13C\]-palmitate and chylomicron-TG \[U-13C\]-palmitate enrichment by GC/MS-MS
Time frame: 2 years
oxidative metabolism of NEFA
will be assessed by using 13C-palmitate
Time frame: 2 years
cardiac and hepatic DFA uptake
will be assessed using PET/CT method with oral administration of 18FTHA
Time frame: 2 years
whole-body organ-specific DFA partitioning
will be determined by whole-body CT (16 mA) followed by PET acquisition of 18FTHA
Time frame: 2 years
Insulin sensitivity
will be determined using the HOMA-IR (based on fasting insulin and glucose levels)
Time frame: 2 years
Insulin secretion rate
will be assessed using deconvolution of plasma C-peptide with standard C-peptide kinetic parameters
Time frame: 2 years
β-cell function
will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin
Time frame: 2 years
WAT size
by biopsy fixed in formalin
Time frame: 2 years
hormonal response
will be determined using a multiplex assay system
Time frame: 2 years
Lipoprotein lipase activity
will be assessed as on frozen 150-mg portions from biopsy
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.